Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006825 · ClinicalTrials.gov registry record · Phase 1
Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer
A Phase 1 study of Breast Cancer, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00006825 is a Phase 1 study of Breast Cancer that has completed, run by NYU Langone Health. The trial reports 1 study location across 1 state.
The verdict
NCT00006825, a Phase 1 study of Breast Cancer, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of liposomal doxorubicin and trastuzumab in treating women who have advanced breast cancer.
Conditions Studied
Interventions
- BIOLOGICAL trastuzumab
- DRUG pegylated liposomal doxorubicin hydrochloride
Study Locations (1)
New York
- NYU School of Medicine's Kaplan Comprehensive Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006825
The ClinicalTrials.gov registry entry for NCT00006825 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which trastuzumab is the first listed.
NCT00006825 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00006825 about?
NCT00006825 is a clinical study titled "Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody ...
What is the current status of trial NCT00006825?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-07.
What conditions does trial NCT00006825 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00006825?
The interventions under investigation include: trastuzumab (BIOLOGICAL), pegylated liposomal doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00006825?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006825 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.